Abstract: Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis Anne-Claire Desbois Hopital Universitaire Pitie Salpetriere Cindy Marques (  cindymarques@ymail.com ) Hopital Universitaire Pitie Salpetriere https://orcid.org/0000-0002-1361-0575 Leila Lefèvre Hopital Universitaire Pitie Salpetriere Serge Barmo Hopital Universitaire Pitie Salpetriere Camille Lorenzo Hopital Universitaire Pitie Salpetriere Mathilde Leclercq Hopital Universitaire Pitie Salpetriere Gaëlle Leroux Hopital Universitaire Pitie Salpetriere Chloé Comarmond Hopital Universitaire Pitie Salpetriere Catherine Chapelon Hopital Universitaire Pitie Salpetriere Fanny Domont Hopital Universitaire Pitie Salpetriere Mathieu Vautier Hopital Universitaire Pitie Salpetriere David Saadoun Hopital Universitaire Pitie Salpetriere Patrice Cacoub Hopital Universitaire Pitie Salpetriere Research article Keywords: sarcoidosis, COVID-19, SARS-CoV-2 Posted Date: July 20th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-41653/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License 1 Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with 2 sarcoidosis 3 Anne-Claire Desbois*1,2,3, Cindy Marques*1,2,3, Leila Lefèvre2,3, Serge Barmo2,3, Camille 4 Lorenzo2,3, Mathilde Leclercq2,3, Gaëlle Leroux2,3, Chloé Comarmond1,2,3, Catherine 5 Chapelon-Abric2,3, Fanny Domont2,3, Mathieu Vauthier2,3, David Saadoun1,2,3, Patrice 6 Cacoub1,2,3 7 * equal contribution 8 9 1. Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology- 10 Immunopathology- Immunotherapy (I3); F-75005, Paris, France; 11 2. Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU 12 i2B), Hôpital Pitié-Salpêtrière, AP-HP, F-75651, Paris, France; 13 3. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical 14 Immunology, F-75013, Paris, France, Centre national de référence des Maladies 15 Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares 16 17 Correspondence: Anne-Claire Desbois, MD, PhD, Department of Internal Medicine and 18 Clinical Immunology, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l’Hôpital, 75013 Paris. 19 Phone: + (33)(1) 42 17 80 68. Fax: + (33)(1) 42 17 80 33. 20 E Mail:anneclaire.desbois@aphp.fr 21 22 Conflict of interest: The authors have declared that no conflict of interest exists. 23 24 Word Count: 1496 words, 10 217 characters (including spaces), 2 tables, 20 references. 25 26 27 Declarations 28 The study was approved by our institutional ethics review board "Ethics committee of 29 research in Sorbonne University". All patients gave informed consent. Ethics approval and consent to participate: 30 31 Consent for publication: 32 Not applicable. 33 34 Availability of data and materials: 35 The datasets used and/or analyzed during the current study are available from the 36 corresponding author on reasonable request. 37 38 Competing interests: 39 The authors declare that they have no competing interests. 40 41 Funding: 42 The authors declare that they have no source of funding. 43 44 Authors' contributions: 45 ACD contributed to the conception and design of the work. 46 ACD and CM wrote the manuscript. 47 ACD, CM, LL, SB, CL, ML, GL, CC, CCA, FD, MV and DS collected the data. 48 CM have drafted the work 49 PC supervised the..